- Home
- GALT vs NYXH Comparison
GALT vs NYXH Comparison
Compare GALT & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GALT | NYXH |
|---|---|---|
| Founded | 2000 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.7M | 188.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GALT | NYXH |
|---|---|---|
| Price | $2.84 | $4.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $8.50 | ★ $11.67 |
| AVG Volume (30 Days) | ★ 322.0K | 43.3K |
| Earning Date | 11-14-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,616,215.00 |
| Revenue This Year | N/A | $75.27 |
| Revenue Next Year | N/A | $277.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.96 |
| 52 Week Low | $1.12 | $4.35 |
| 52 Week High | $7.13 | $11.87 |
Technical Indicators
Market Signals| Indicator | GALT | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 37.78 | 46.10 |
| Support Level | $2.61 | $4.70 |
| Resistance Level | $3.30 | $4.83 |
| Average True Range (ATR) | 0.23 | 0.17 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 21.05 | 28.57 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.